_id
691053dbccc777a4e85d5546
Ticker
CPRX
Name
Catalyst Pharmaceuticals Inc
Exchange
NASDAQ
Address
355 Alhambra Circle, Coral Gables, FL, United States, 33134
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://catalystpharma.com
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Last Close
22.94
Volume
527440
Current Price
23.62
Change
2.9642545771578015
Last Updated
2025-11-29T11:48:11.652Z
Image
data:image/webp;base64,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
Ipo Date
2006-11-08T00:00:00.000Z
Market Cap
2877378816
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9873296296296298
Sentiment Sources
27
Rating
4.8571
Target Price
34.8571
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
148392000
Cost Of Revenue
25311000
Gross Profit
123081000
Operating Expenses
56814001
Operating Income
66266999
Interest Expense
-
Pretax Income
71035000
Net Income
52783000
Eps
0.41531921809797534
Dividends Per Share
-
Shares Outstanding
122912387
Income Tax Expense
18252000
EBITDA
80451001
Operating Margin
44.65671936492534
Total Other Income Expense Net
4768001
Cash
689892000
Short Term Investments
-
Receivables
106769000
Inventories
28029000
Total Current Assets
852453000
Property Plant Equipment
3087000
Total Assets
1051602000
Payables
9096000
Short Term Debt
428000
Long Term Debt
-
Total Liabilities
131357000
Equity
920245000
Depreciation
9416000
Change In Working Capital
-39623000
Cash From Operations
32438000
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
4654000
Net Change In Cash
37092000
PE
13.6901
PB
3.262033895625622
ROE
5.735755152160566
ROA
5.019294371825082
FCF
32438000
Fcf Percent
0.21859668984850936
Piotroski FScore
3
Health Score
73
Deep Value Investing Score
7
Defensive Investing Score
8.5
Dividend Investing Score
3
Economic Moat Investing Score
9
Garp Investing Score
4.5
Growth Investing Score
3
Momentum Investing Score
4.5
Net Net Investing Score
4
Quality Investing Score
8
Value Investing Score
6.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
148392000
Quarters > 0 > income Statement > cost Of Revenue
25311000
Quarters > 0 > income Statement > gross Profit
123081000
Quarters > 0 > income Statement > operating Expenses
56814001
Quarters > 0 > income Statement > operating Income
66266999
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
71035000
Quarters > 0 > income Statement > net Income
52783000
Quarters > 0 > income Statement > eps
0.41531921809797534
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
127090194
Quarters > 0 > income Statement > income Tax Expense
18252000
Quarters > 0 > income Statement > EBITDA
80451001
Quarters > 0 > income Statement > operating Margin
44.65671936492534
Quarters > 0 > income Statement > total Other Income Expense Net
4768001
Quarters > 0 > balance Sheet > cash
689892000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
106769000
Quarters > 0 > balance Sheet > inventories
28029000
Quarters > 0 > balance Sheet > total Current Assets
852453000
Quarters > 0 > balance Sheet > property Plant Equipment
3087000
Quarters > 0 > balance Sheet > total Assets
1051602000
Quarters > 0 > balance Sheet > payables
9096000
Quarters > 0 > balance Sheet > short Term Debt
428000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
131357000
Quarters > 0 > balance Sheet > equity
920245000
Quarters > 0 > cash Flow > net Income
52783000
Quarters > 0 > cash Flow > depreciation
9416000
Quarters > 0 > cash Flow > change In Working Capital
-39623000
Quarters > 0 > cash Flow > cash From Operations
32438000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
4654000
Quarters > 0 > cash Flow > net Change In Cash
37092000
Quarters > 0 > ratios > PE
0.41531921809797534
Quarters > 0 > ratios > PB
3.262033895625622
Quarters > 0 > ratios > ROE
5.735755152160566
Quarters > 0 > ratios > ROA
5.019294371825082
Quarters > 0 > ratios > FCF
32438000
Quarters > 0 > ratios > Piotroski FScore
3
Quarters > 0 > ratios > fcf Percent
0.21859668984850936
Quarters > 0 > health Score
73
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
146563000
Quarters > 1 > income Statement > cost Of Revenue
29958000
Quarters > 1 > income Statement > gross Profit
116605000
Quarters > 1 > income Statement > operating Expenses
50307000
Quarters > 1 > income Statement > operating Income
66298000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
69293000
Quarters > 1 > income Statement > net Income
52108000
Quarters > 1 > income Statement > eps
0.40855150005389546
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
127543284
Quarters > 1 > income Statement > income Tax Expense
17185000
Quarters > 1 > income Statement > EBITDA
78753000
Quarters > 1 > income Statement > operating Margin
45.235154848085806
Quarters > 1 > income Statement > total Other Income Expense Net
2995000
Quarters > 1 > balance Sheet > cash
652800000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
66313000
Quarters > 1 > balance Sheet > inventories
18650000
Quarters > 1 > balance Sheet > total Current Assets
758739000
Quarters > 1 > balance Sheet > property Plant Equipment
3233000
Quarters > 1 > balance Sheet > total Assets
971915000
Quarters > 1 > balance Sheet > payables
5528000
Quarters > 1 > balance Sheet > short Term Debt
419000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
115888000
Quarters > 1 > balance Sheet > equity
856027000
Quarters > 1 > cash Flow > net Income
52108000
Quarters > 1 > cash Flow > depreciation
9460000
Quarters > 1 > cash Flow > change In Working Capital
946000
Quarters > 1 > cash Flow > cash From Operations
71298000
Quarters > 1 > cash Flow > capital Expenditures
26000
Quarters > 1 > cash Flow > cash From Investing
-26000
Quarters > 1 > cash Flow > cash From Financing
872000
Quarters > 1 > cash Flow > net Change In Cash
72144000
Quarters > 1 > ratios > PE
0.40855150005389546
Quarters > 1 > ratios > PB
3.519249238727283
Quarters > 1 > ratios > ROE
6.087191175044712
Quarters > 1 > ratios > ROA
5.361374194245381
Quarters > 1 > ratios > FCF
71272000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.48628917257425136
Quarters > 1 > health Score
74
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
141421000
Quarters > 2 > income Statement > cost Of Revenue
17911000
Quarters > 2 > income Statement > gross Profit
123510000
Quarters > 2 > income Statement > operating Expenses
60143000
Quarters > 2 > income Statement > operating Income
63367000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
71286000
Quarters > 2 > income Statement > net Income
56737000
Quarters > 2 > income Statement > eps
0.4468958238157501
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
126958000
Quarters > 2 > income Statement > income Tax Expense
14549000
Quarters > 2 > income Statement > EBITDA
72827000
Quarters > 2 > income Statement > operating Margin
44.80734827218023
Quarters > 2 > income Statement > total Other Income Expense Net
7919000
Quarters > 2 > balance Sheet > cash
580656000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
72258000
Quarters > 2 > balance Sheet > inventories
19778000
Quarters > 2 > balance Sheet > total Current Assets
685718000
Quarters > 2 > balance Sheet > property Plant Equipment
3397000
Quarters > 2 > balance Sheet > total Assets
908872000
Quarters > 2 > balance Sheet > payables
11197000
Quarters > 2 > balance Sheet > short Term Debt
410000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
114589000
Quarters > 2 > balance Sheet > equity
794283000
Quarters > 2 > cash Flow > net Income
56737000
Quarters > 2 > cash Flow > depreciation
9460000
Quarters > 2 > cash Flow > change In Working Capital
-7051000
Quarters > 2 > cash Flow > cash From Operations
60043000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
3060000
Quarters > 2 > cash Flow > net Change In Cash
63103000
Quarters > 2 > ratios > PE
0.4468958238157501
Quarters > 2 > ratios > PB
3.7754150095117236
Quarters > 2 > ratios > ROE
7.143171892134164
Quarters > 2 > ratios > ROA
6.24257321162936
Quarters > 2 > ratios > FCF
60043000
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.42456919410837146
Quarters > 2 > health Score
76
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
141820000
Quarters > 3 > income Statement > cost Of Revenue
21643000
Quarters > 3 > income Statement > gross Profit
120177000
Quarters > 3 > income Statement > operating Expenses
57334000
Quarters > 3 > income Statement > operating Income
62843000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
74181000
Quarters > 3 > income Statement > net Income
55936000
Quarters > 3 > income Statement > eps
0.4429521697814381
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
126280000
Quarters > 3 > income Statement > income Tax Expense
18245000
Quarters > 3 > income Statement > EBITDA
72301000
Quarters > 3 > income Statement > operating Margin
44.31180369482443
Quarters > 3 > income Statement > total Other Income Expense Net
11338000
Quarters > 3 > balance Sheet > cash
517553000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
65487000
Quarters > 3 > balance Sheet > inventories
19541000
Quarters > 3 > balance Sheet > total Current Assets
623609000
Quarters > 3 > balance Sheet > property Plant Equipment
3584000
Quarters > 3 > balance Sheet > total Assets
851411000
Quarters > 3 > balance Sheet > payables
16593000
Quarters > 3 > balance Sheet > short Term Debt
402000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
123779000
Quarters > 3 > balance Sheet > equity
727632000
Quarters > 3 > cash Flow > net Income
55936000
Quarters > 3 > cash Flow > depreciation
9458000
Quarters > 3 > cash Flow > change In Working Capital
4447000
Quarters > 3 > cash Flow > cash From Operations
70877000
Quarters > 3 > cash Flow > capital Expenditures
88000
Quarters > 3 > cash Flow > cash From Investing
-88000
Quarters > 3 > cash Flow > cash From Financing
4433000
Quarters > 3 > cash Flow > net Change In Cash
75222000
Quarters > 3 > ratios > PE
0.4429521697814381
Quarters > 3 > ratios > PB
4.09923367856279
Quarters > 3 > ratios > ROE
7.687402423202938
Quarters > 3 > ratios > ROA
6.5698000143291555
Quarters > 3 > ratios > FCF
70789000
Quarters > 3 > ratios > Piotroski FScore
4
Quarters > 3 > ratios > fcf Percent
0.49914680581018195
Quarters > 3 > health Score
77
Valuation > metrics > PE
13.6901
Valuation > metrics > PB
3.262033895625622
Valuation > final Score
77.37966104374378
Valuation > verdict
4.4% Overvalued
Profitability > metrics > ROE
5.735755152160566
Profitability > metrics > ROA
6.191895623571035
Profitability > metrics > Net Margin
0.3556997681815731
Profitability > final Score
60
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
0.1427413351879119
Risk > metrics > Interest Coverage
7.037700930575517
Risk > final Score
88
Risk > verdict
Low
Liquidity > metrics > Current Ratio
89.50577488450232
Liquidity > metrics > Quick Ratio
86.56278874422512
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
64.80750761272716
Prev Valuations > 1
62.24584990488277
Prev Valuations > 2
59.0076632143721
Prev Profitabilities > 0
63
Prev Profitabilities > 1
69
Prev Profitabilities > 2
72
Prev Risks > 0
88
Prev Risks > 1
100
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:41.001Z
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACatalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift - Investor's Business Daily
12/15/2025
Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift Investor's Business Daily
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$34.8571
Analyst Picks
Strong Buy
6
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 78.47% of the total shares of Catalyst Pharmaceuticals Inc
1.
BlackRock Inc(15.4427%)
since
2025/06/30
2.
Vanguard Group Inc(7.1622%)
since
2025/06/30
3.
iShares Core S&P Small-Cap ETF(5.5711%)
since
2025/08/31
4.
State Street Corp(4.4761%)
since
2025/06/30
5.
Vanguard Total Stock Mkt Idx Inv(2.9672%)
since
2025/07/31
6.
Renaissance Technologies Corp(2.6567%)
since
2025/06/30
7.
Morgan Stanley - Brokerage Accounts(2.6011%)
since
2025/06/30
8.
Deerfield Management Co(2.3527%)
since
2025/06/30
9.
Geode Capital Management, LLC(2.3422%)
since
2025/06/30
10.
iShares Russell 2000 ETF(2.2717%)
since
2025/08/31
11.
Fundsmith LLP(2.2135%)
since
2025/06/30
12.
Smithson Investment Trust Ord(2.2135%)
since
2025/05/31
13.
Goldman Sachs Group Inc(1.9705%)
since
2025/06/30
14.
Bank of America Corp(1.9329%)
since
2025/06/30
15.
Dimensional Fund Advisors, Inc.(1.5585%)
since
2025/06/30
16.
Avantis US Small Cap Value ETF(1.4709%)
since
2025/08/30
17.
American Century Companies Inc(1.4364%)
since
2025/06/30
18.
Royce & Associates, LP(1.2933%)
since
2025/06/30
19.
Charles Schwab Investment Management Inc(1.1734%)
since
2025/06/30
20.
Boston Partners Global Investors, Inc(1.0481%)
since
2025/06/30
21.
Northern Trust Corp(1.0418%)
since
2025/06/30
22.
Vanguard Institutional Extnd Mkt Idx Tr(1.0057%)
since
2025/07/31
23.
Arrowstreet Capital Limited Partnership(0.9998%)
since
2025/06/30
24.
Amvescap Plc.(0.9917%)
since
2025/06/30
25.
SPDR® S&P Biotech ETF(0.9528%)
since
2025/08/31
26.
Fidelity Small Cap Index(0.9482%)
since
2025/06/30
27.
Allianz Asset Management AG(0.8479%)
since
2025/06/30
28.
Qube Research & Technologies(0.8288%)
since
2025/06/30
29.
iShares Russell 2000 Growth ETF(0.8288%)
since
2025/08/31
30.
SPDR® Portfolio S&P 600™ Sm Cap ETF(0.8281%)
since
2025/08/29
31.
iShares S&P Small-Cap 600 Growth ETF(0.8061%)
since
2025/08/31
32.
Vanguard Tax-Managed Small Cap Adm(0.6097%)
since
2025/07/31
33.
Fidelity Extended Market Index(0.5017%)
since
2025/07/31
34.
Pacer US Small Cap Cash Cows 100 ETF(0.4739%)
since
2025/08/29
35.
Kennedy Small Cap Value(0.4616%)
since
2025/06/30
36.
SPDR® S&P 600 Small Cap Growth ETF(0.4558%)
since
2025/08/31
37.
Vanguard Russell 2000 ETF(0.4506%)
since
2025/07/31
38.
Schwab US Small-Cap ETFâ„¢(0.4428%)
since
2025/08/30
39.
Macquarie Small Cap Growth C(0.4239%)
since
2025/07/31
40.
T. Rowe Price Integrated US Sm Gr Eq(0.411%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.